The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study

The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study

Bibliographic Details
Main Authors:	Jade N. Young, BS, Hannah Verma, BA, Nour El Kashlan, MD, Dina Poplausky, BA, Angela J. Lamb, MD, Emma Guttman-Yassky, MD, PhD, Nicholas Gulati, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	JAAD Case Reports
Subjects:	biologics cirAE cutaneous immune-related adverse event immune checkpoint inhibitor immunotherapy oncodermatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512623004009

Similar Items

A case of urticarial vasculitis associated with atezolizumab
by: Jade N. Young, BS, et al.
Published: (2024-01-01)

Erythematous desquamating rash after initiation of chemotherapy
by: Jack Newcomer, BA, et al.
Published: (2023-04-01)

Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network
by: Qi Wang, et al.
Published: (2022-06-01)

Genomic and phenotypic characterization of multidrug-resistant Salmonella enterica serovar Reading isolates involved in a turkey-associated foodborne outbreak
by: Sathesh K. Sivasankaran, et al.
Published: (2024-01-01)

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
by: Ting Cao, et al.
Published: (2023-06-01)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
by: Agnese Paderi, et al.
Published: (2021-02-01)

Comparative Study of Cellular Immune Response in Cutaneous Blastomycosis
by: Haider Faisal, et al.
Published: (2012-12-01)

Cutaneous manifestations associated with immune checkpoint inhibitors
by: Tomoya Watanabe, et al.
Published: (2023-02-01)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
by: Vasiliki Nikolaou, et al.
Published: (2023-03-01)

Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
by: Prasanna Duraisamy, et al.
Published: (2023-07-01)

High-dose vitamin D for the management acute radiation dermatitis
by: Cuong V. Nguyen, MD, et al.
Published: (2023-09-01)

Pseudocellulitis in oncology patients: A single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy
by: Jolanta J. Pach, BS, et al.
Published: (2023-09-01)

Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
by: Almog Shalit, et al.
Published: (2023-01-01)

Organisation sociale et sémantique des prénoms du cira1, une langue gur de Côte d’Ivoire
by: N’Guessan Edmonde-Andréa ALLA
Published: (2021-04-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024-02-01)

Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 1: Mycosis fungoides
by: Sachi I. Desse, et al.
Published: (2023-12-01)

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
by: Roser Calvo
Published: (2019-04-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Fever of unknown origin associated with immune checkpoint inhibitors
by: Xu Tong, et al.
Published: (2024-03-01)

Identification of fatty acid metabolism–related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma
by: Yujian Xu, et al.
Published: (2022-11-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival
by: Lisa Yang, et al.
Published: (2024-04-01)

Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis
by: Andrés Ponce, et al.
Published: (2022-08-01)

Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors
by: Martina Morelli, et al.
Published: (2024-03-01)

Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
by: Nina B. Curkovic, et al.
Published: (2024-01-01)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
by: Lukas Kraehenbuehl, et al.
Published: (2023-06-01)

Treatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approach
by: Alana Deutsch, MD, et al.
Published: (2023-04-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
by: Tristan V.M. Bruijn, MD, et al.
Published: (2024-05-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
by: Sae Ohwada, et al.
Published: (2022-06-01)

Immune deposits in cutaneous lesions of Wegener′s granulomatosis: Predictor of an active disease
by: Seema Chhabra, et al.
Published: (2011-01-01)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
by: Yi-Shan Teng, et al.
Published: (2023-07-01)

Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
by: Haoran Mei, et al.
Published: (2023-01-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
by: Daisuke Hazama, MD, PhD, et al.
Published: (2024-01-01)

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
by: Chieh-Hsun Chen, et al.
Published: (2022-04-01)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
by: Gunther Glehr, et al.
Published: (2022-09-01)

Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service
by: Jolanta J. Pach, BS, et al.
Published: (2024-06-01)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
by: Adrian Chye, et al.
Published: (2022-07-01)

Recurrent bilateral cutaneous squamous cell carcinoma arising within hypertrophic lichen planus with metastasis while on cemiplimab
by: Melissa C. Leeolou, BS, et al.
Published: (2022-11-01)